Clinical trials: Pyelonephritis
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The purpose of this study is to evaluate the efficacy and safety of HRS-8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
- Trial name
- NCT06569056
- Testing
- HRS-8427, Imipenem and Cilastatin Sodium
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
This is a Phase 2 randomized open label multicentre three arm comparative study evaluating the efficacy safety tolerability and pharmacokinetics of intravenous ertapenem zidebactam ERT ZID compared with ceftazidime avibactam CAZ…
- Trial name
- NCT07840105
- Testing
- Ertapenem-zidebactam, Ceftazidime-Avibactam, Ertapenam-Zidebactam
- Where
- 19 sites in India
- Volunteers
- 279 people
- Sponsor
- Wockhardt
Acute Pyelonephritis, Complicated Urinary Tract Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract…
- Trial name
- NCT06672978
- Testing
- Meropenem-Vaborbactam, Antibiotics
- Where
- 26 sites in United States, Bulgaria and 4 more
- Volunteers
- 66 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Complicated Urinary Tract Infection, Acute Pyelonephritis
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
- Trial name
- NCT04979806
- Testing
- Cefepime-zidebactam (FEP-ZID), Meropenem
- Where
- 48 sites in United States, Bulgaria and 7 more
- Volunteers
- 530 people
- Sponsor
- Wockhardt
Intra Abdominal Infections, Appendicitis Acute
Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study
The NATURAL Study is a prospective, observational, pragmatic study of RNA biomarkers of infections to aid in the diagnosis of abdominal pain.
- Conditions
- Intra Abdominal Infections, Appendicitis Acute, Pyelonephritis, Diverticulitis
- Trial name
- NATURAL (NCT07579312)
- Testing
- TruNAV, an RNA-based blood test for host immune activation by infections
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- True Bearing Diagnostics, Inc.
Complicated Urinary Tract Infection, Acute Pyelonephritis
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the…
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- Integral-2 (NCT05905055)
- Testing
- co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT
- Where
- 54 sites in China, Croatia and 12 more
- Volunteers
- 126 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Urinary Tract Infection, Acute Pyelonephritis
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication)…
- Trial name
- PIVOT-PO (NCT06059846)
- Testing
- TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 1,690 people
- Sponsor
- Spero Therapeutics
Complicated Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated…
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis, cUTI, AP
- Trial name
- Integral-1 (NCT05887908)
- Testing
- co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin
- Where
- 61 sites in Bulgaria, China and 7 more
- Volunteers
- 614 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Urinary Tract Infections, Acute Pyelonephritis
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
- Trial name
- CERTAIN-1 (NCT03840148)
- Testing
- Cefepime/VNRX-5133 (taniborbactam), Meropenem
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 661 people
- Sponsor
- Venatorx Pharmaceuticals, Inc.
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Complicated Urinary Tract Infection, Acute Pyelonephritis
Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection
Sulopenem etzadroxil/probenecid is available to clinicians through an Expanded Access Program for the treatment of complicated urinary tract infections due to quinolone nonsusceptible uropathogens after an initial course of…
- Trial name
- NCT04682834
- Testing
- Sulopenem Etzadroxil/Probenecid
- Sponsor
- Iterum Therapeutics, International Limited
Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.
- Trial name
- NCT06144060
- Testing
- HRS -8427, Imipenem and Cilastatin Sodium
- Volunteers
- 126 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Urinary Tract Infections, Pyelonephritis
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis.
- Trial name
- NCT06128213
- Testing
- NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))
- Volunteers
- 13 people
- Sponsor
- NeuroRx, Inc.
Urinary Tract Infections in Children, Dexamethasone
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with…
- Conditions
- Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis
- Trial name
- NCT04654507
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Complicated Urinary Tract Infection, Acute Pyelonephritis
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
This is a Phase III, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-TAZ vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
- Trial name
- NCT03630081
- Testing
- WCK 4282 (FEP-TAZ) 4 g, Meropenem, ciprofloxacin 500 mg Optional Oral Switch
- Volunteers
- 1,004 people
- Sponsor
- Wockhardt
Complicated Urinary Tract Infection, Pyelonephritis
MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.
- Trial name
- NCT03230838
- Testing
- Ceftolozane/Tazobactam, Meropenem
- Where
- 52 sites in United States, Greece and 8 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with…
- Trial name
- NCT05204368
- Testing
- Combination of Imipenem/Cilastatin and XNW4107, Meropenem
- Where
- United States
- Volunteers
- 780 people
- Sponsor
- Evopoint Biosciences Inc.
Complicated Urinary Tract Infection, Acute Pyelonephritis
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
The key purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) compared to intravenous (IV) ertapenem, in participants with complicated Urinary Tract…
- Trial name
- ADAPT-PO (NCT03788967)
- Testing
- TBPM-PI-HBr, Ertapenem, Dummy Infusion
- Where
- 96 sites in United States, Bulgaria and 13 more
- Volunteers
- 1,372 people
- Sponsor
- Spero Therapeutics
Urinary Tract Infections, Pyelonephritis Acute
Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous sulopenem and oral sulopenem etzadroxil/probenecid in adolescent patients.
- Conditions
- Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
- Trial name
- NCT04700787
- Testing
- Sulopenem
- Where
- United States
- Sponsor
- Iterum Therapeutics, International Limited
Complicated Urinary Tract Infection, Acute Pyelonephritis
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
Phase 2, randomised, double-blind,double-dummy study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis.Treatment duration for each cohort was 7 to 14 days.
- Trial name
- NCT05060419
- Testing
- Meropenem- FL058, Piperacillin -tazobactam, Saline
- Volunteers
- 150 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.